Enzyme screening kits and samples global distribution agreement signed between Strem and Novozymes

Strem Chemicals, Inc., a manufacturer of specialty chemicals for research and development, and Novozymes, the world’s largest producer of industrial enzymes, today announced the signing of a distribution agreement.

The agreement grants Strem global distribution rights for research quantities of Novozymes’ Enzyme Screening Kits® and samples for its lipase and protease enzymes for biocatalytic applications in the pharmaceutical and specialty chemical industries. Lipases are one of the most commonly used classes of enzymes in biocatalysis, while proteases have a broad range of opportunities in process design.

Biocatalysis, the application of enzymes which can replace chemical catalysts in synthetic processes, is becoming increasingly widespread in the pharmaceutical and fine chemical industries. Novozymes offers a range of enzymes for biocatalysis and this new distribution agreement enables interested pharmaceutical manufacturers to test Novozymes' enzymes in their production processes.

Novozymes' Enzyme Screening Kits offer a fast, efficient way of easily accessing Novozymes’ portfolio of enzymes. Containing proven enzymes used in the biocatalysis process that not only enable new, more sustainable routes for the production of intermediates and APIs, but offer commercial benefits such as better and greener production, fewer side reactions and purification steps - all of which add up to lower costs.

"Novozymes extensive experience in biocatalysis and industry reputation for providing proven solutions, makes the company the ideal partner for Strem"

"The addition of Novozymes' Screening Kits and samples to our portfolio will help broaden our reach to the market, providing customers with powerful enzymes for biocatalytic synthesis and enzyme development."

Ephraim Honig, Chief Operating Officer at Strem.

"Strem is well regarded in the catalytic arena and the pharmaceutical industry. We are delighted to announce the signing of this distribution agreement", comments Garrett Screws, Strategic Account Manager at Novozymes. He continues, "Working together we will provide more customers with the opportunity to have complete access to Novozymes' portfolio of enzymes for screening purposes."

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Liver X receptor beta offers new hope in treating depression and anxiety